A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
COMPANY OVERVIEW We are a fully integrated, leading central nervous system, or CNS, precision neuroscience biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Normal brain function requires a delicate balance of excitation and inhibition in neuronal circuits, which, when dysregulated, can lead to abnormal function and both rare and more prevalent neurological disorders. We are applying genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms, using our understanding of shared biological targets and circuits in the brain.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | - | - | 0 |
| Net Income | -303M | -303M | -183M | -123M | -214M |
| EPS | $-13.48 | $-13.48 | $-10.21 | $-18.69 | $-69.65 |
| Free Cash Flow | -249M | -249M | -132M | -111M | -185M |
| ROIC | -49.5% | -34.5% | -41.0% | -143.3% | -223.2% |
| Gross Margin | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.07 | 0.08 | 0.26 | 0.51 |
| Dividends/Share | $0.00 | - | - | - | - |
| Operating Income | -326M | -326M | -200M | -126M | -215M |
| Operating Margin | 0.0% | - | - | - | - |
| ROE | -34.5% | -45.8% | -41.0% | -176.9% | -281.2% |
| Shares Outstanding | 22M | 22M | 18M | 20M | 13M |
| Metric | 2022 | 2023 | |||
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0 | N/A | N/A | 0 | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| R&D | 155M | 87M | 152M | 267M | 267M |
| SG&A | 60M | 42M | 56M | 59M | 59M |
| EBIT | -215M | -126M | -200M | -326M | -326M |
| Op. Margin | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -214M | -123M | -183M | -303M | -303M |
| Net Margin | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||
| ROIC | N/M | -143.3% | -41.0% | -34.5% | -49.5% |
| ROE | -281.2% | -176.9% | -41.0% | -45.8% | -34.5% |
| ROA | -185.9% | -140.2% | -37.8% | -42.7% | -32.3% |
| Cash Flow | |||||
| Op. Cash Flow | -185M | -111M | -132M | -249M | -249M |
| Free Cash Flow | -185M | -111M | -132M | -249M | -249M |
| Owner Earnings | -214M | -136M | -173M | -283M | -283M |
| CapEx | 444K | 50K | 0 | 56K | 56K |
| Maint. CapEx | 419K | 432K | 358K | 140K | 140K |
| Growth CapEx | 25K | 0 | N/A | 0 | 0 |
| D&A | 419K | 432K | 358K | 140K | 140K |
| CapEx/OCF | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 29M | 25M | 41M | 34M | 34M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||
| Net Debt | N/A | N/A | N/A | N/A | -357M |
| Cash & Equiv. | 62M | 81M | 215M | 357M | 357M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.51 | 0.26 | 0.08 | 0.07 | 0.00 |
| Interest Coverage | N/A | N/A | N/A | N/A | N/A |
| Equity | 76M | 70M | 445M | 878M | 878M |
| Total Assets | 115M | 88M | 483M | 938M | 938M |
| Total Liabilities | 39M | 18M | 38M | 60M | 60M |
| Intangibles | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -531M | -654M | -837M | -1.1B | -1.1B |
| Working Capital | 76M | 69M | 367M | 551M | 551M |
| Current Assets | 111M | 85M | 404M | 611M | 611M |
| Current Liabilities | 34M | 16M | 38M | 60M | 60M |
| Per Share Data | |||||
| EPS | -69.65 | -18.69 | -10.21 | -13.48 | -13.48 |
| Owner EPS | -16.17 | -6.77 | -9.69 | -12.59 | -12.59 |
| Book Value | 5.75 | 3.46 | 24.88 | 39.03 | 39.03 |
| Cash Flow/Share | -13.98 | -5.51 | -7.36 | -11.07 | -13.47 |
| Dividends/Share | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 13.2M | 20.2M | 17.9M | 22.5M | 22.5M |
| Valuation | |||||
| P/E Ratio | N/A | N/A | N/A | N/A | -25.5 |
| P/FCF | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 5.9 | 6.2 | 3.1 | 6.9 | 8.8 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | -41.3% | -25.8% | -9.6% | -4.1% | -3.2% |
| Market Cap | 449M | 432M | 1.4B | 6.1B | 7.7B |
| Avg. Price | 101.17 | 23.71 | 54.47 | 81.87 | 343.60 |
| Year-End Price | 33.90 | 21.41 | 77.00 | 268.95 | 343.60 |
Praxis Precision Medicines, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Praxis Precision Medicines, Inc. (PRAX) has a 5-year average return on invested capital (ROIC) of -73.0%. This is below average and may indicate limited pricing power.
Praxis Precision Medicines, Inc. (PRAX) has a market capitalization of $7.7B. It is classified as a mid-cap stock.
Praxis Precision Medicines, Inc. (PRAX) does not currently pay a regular dividend.
Praxis Precision Medicines, Inc. (PRAX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Praxis Precision Medicines, Inc. (PRAX) generated $-249 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Praxis Precision Medicines, Inc. (PRAX) has a debt-to-equity ratio of 0.07. This indicates a conservatively financed balance sheet.
Praxis Precision Medicines, Inc. (PRAX) reported earnings per share (EPS) of $-13.48 in its most recent fiscal year.
Praxis Precision Medicines, Inc. (PRAX) has a return on equity (ROE) of -45.8%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 4 years of financial data for Praxis Precision Medicines, Inc. (PRAX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Praxis Precision Medicines, Inc. (PRAX) has a book value per share of $39.03, based on its most recent annual SEC filing.